Drug
Anti-SIRPa Monoclonal Antibody BI 770371 clinical trials
Also written BI 770371.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2022
How studies write it
Studies that test it under each name
Development codes
Studies by the year they started
3 studies that test it; most in 2025 (2)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 0
Often tested with
Tested in the same studies.
Cetuximab (1) · Anti-SIRPa Monoclonal Antibody BI 765063 (1) · Zirconium-89 (1)
Studies
Open first, then newest update. How each study uses Anti-SIRPa Monoclonal Antibody BI 770371 is read from its arms, and is right about nine times in ten.
Testing it · 3
- A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab AloneActive, not recruitingPhase 1Boehringer IngelheimNCT06806852Written as BI 770371
- A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking EzabenlimabActive, not recruitingPhase 1Boehringer IngelheimNCT05068102Written as BI 770371
- A Study to Test How Well BI 770371 is Tolerated by People With Cirrhosis Caused by a Liver Disease Called MASHCompletedPhase 2Boehringer IngelheimNCT06675929Written as BI 770371